Composition Lenvatinib 4 mg
Lenvat (lenvatinib) is a kinase inhibitor that is indicated for
- Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
- Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
- Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma
DOSAGE AND ADMINISTRATION
- Recommended dose (DTC): 24 mg orally, once daily.
- Recommended dose (RCC): 18 mg lenvatinib 5 mg everolimus, orally, once daily.
- Recommended dose (HCC): 12 mg orally, once daily (for adults weighing >_60 Kg). 8 mg orally, once daily for adults weighing <60 kg).
- Administration Instructions.
- Dose Modifications for DTC and RCC.
- In patients with severe renal or hepatic impairment, the dose is 14 mg once daily in DTC and 10 mg once daily in RCC.
lenvatinib Side Effects
The most common side effects of lenvatinib in people treated for thyroid cancer include:
- 1.tiredness 2.joint and muscle pain 3.weight loss
- 4.mouth sores 5.vomiting 6.stomach (abdomen) pain
- 7. decreased appetite 8.nausea 9.headache
- 10.rash, redness, itching, or peeling of your skin on your hands and feet
- 11. Hoarseness
The most common side effects of lenvatinib in people treated for kidney cancer include:
- 1.tiredness 2.decreased appetite 3.nausea
- 4. swelling in your arms and legs 5.stomach (abdomen) pain 6.rash
- 7.joint and muscle pain 8.vomiting 9.mouth sores
- 10.cough 11.trouble breathing 12.weight loss 13.bleeding
Lenvatinib may cause fertility problems in males and females. Talk to your healthcare provider if this is a concern for you.
Related warnings
Lenvat’s brand name is LENVIMA by Eisai Inc. Lenvat is a generic oncologic prescription medicine from Natco (similar drugs like Lenvanix), which is one of the biggest pharmaceutical company in India.
| 药名 | 乐伐替尼, 仑伐替尼 |
| 厂家 | 印度（NATCO） |
| 成分 | lenvatinib 4mg |
| 说明 |
仑伐替尼
仑伐替尼（乐伐替尼）由Eisai Co.开发，针对VEGFR-1、VEGFR-2、VEGFR-3、FGFR1、PDGFR、cKit、Ret等靶点，目前已获批的适应症有肝癌、甲状腺癌和肾癌。
肝癌，肾癌
|
* 以上中文信息由印度阿努卡药房收集的Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）中文网络信息和软件翻译获得，阿努卡药房认为Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）中文产品介绍信息存在与Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）实际数据不一致的可能。阿努卡药房请用户把Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）页面数据作为参考。印度阿努卡药房建议用户在实际使用Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）数据或者信息时，以Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）制造商公开发布的Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）商品信息为参考。使用方法，以用户医生建议使用Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）决定为参考。用户任何关于Lenvat 4mg 30 Capsule（乐伐替尼, 仑伐替尼）的建议，可以通知印度阿努卡药房，或通知阿努卡在线客服人员。谢谢
